国家医保局：统一规范常用美容整形类价格项目；ST百灵申请撤销其他风险警示｜医药早参

Group 1 - Suzhou Haike's founder, Zhong Dafa, has applied for a retrial with the Supreme People's Court regarding a lawsuit against the company and its actual controller, Wu Jie, highlighting the reliance on judicial remedies in commercial contract disputes [1] - The case involves complex legal issues related to the responsibility of the actual controller and the joint liability of subsidiaries, with the Supreme Court's retrial threshold being high and requiring statutory grounds [1] Group 2 - ST Bailing has announced that it meets the Shenzhen Stock Exchange's requirements for the removal of other risk warnings, indicating progress in internal control rectification despite a "qualified opinion" in its 2024 internal control audit [2] - The company has applied to the Shenzhen Stock Exchange to revoke the risk warning, which may pave the way for a future delisting application, although there remains uncertainty regarding the exchange's acceptance of the audit report [2] Group 3 - Nanhua Biomedical has authorized its management to publicly sell a 52% stake in Nanhua Peace Hospital Management (Hunan) Co., Ltd. to optimize its business structure, as the subsidiary reported a net loss of 2.31 million yuan in 2024 [3] - The sale of the loss-making asset may help improve the company's financial situation, although the final transaction price and buyer remain uncertain [3] Group 4 - The National Healthcare Security Administration has issued guidelines to standardize pricing for commonly used cosmetic surgery services, aiming to create a more transparent and orderly market environment for the cosmetic surgery industry [4] - This initiative is expected to promote high-quality development in the industry by guiding medical institutions in reasonable pricing and encouraging innovation in related pharmaceuticals and consumables [4]